John Seibyl

1991–2025 年に発表

121
論文数
25,691
被引用数
84
h 指数
117
i10 指数

被引用数

John Seibyl の年別被引用数1986 年: 被引用 1 件1992 年: 被引用 2 件1993 年: 被引用 6 件1994 年: 被引用 14 件1995 年: 被引用 19 件1996 年: 被引用 34 件1997 年: 被引用 99 件1998 年: 被引用 74 件1999 年: 被引用 129 件2000 年: 被引用 180 件2001 年: 被引用 199 件2002 年: 被引用 238 件2003 年: 被引用 240 件2004 年: 被引用 223 件2005 年: 被引用 241 件2006 年: 被引用 217 件2007 年: 被引用 250 件2008 年: 被引用 190 件2009 年: 被引用 212 件2010 年: 被引用 134 件2011 年: 被引用 154 件2012 年: 被引用 174 件2013 年: 被引用 150 件2014 年: 被引用 141 件2015 年: 被引用 182 件2016 年: 被引用 172 件2017 年: 被引用 209 件2018 年: 被引用 198 件2019 年: 被引用 627 件2020 年: 被引用 764 件2021 年: 被引用 772 件2022 年: 被引用 712 件2023 年: 被引用 626 件2024 年: 被引用 1,124 件2025 年: 被引用 674 件2026 年: 被引用 45 件1987〜1991 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,416 件、この内訳の 27.7%イギリス: 引用元論文 1,118 件、この内訳の 9.1%ドイツ: 引用元論文 897 件、この内訳の 7.3%中国: 引用元論文 705 件、この内訳の 5.7%カナダ: 引用元論文 625 件、この内訳の 5.1%イタリア: 引用元論文 502 件、この内訳の 4.1%スウェーデン: 引用元論文 489 件、この内訳の 4%オランダ: 引用元論文 428 件、この内訳の 3.5%スペイン: 引用元論文 389 件、この内訳の 3.1%フランス: 引用元論文 389 件、この内訳の 3.1%スイス: 引用元論文 316 件、この内訳の 2.6%オーストラリア: 引用元論文 304 件、この内訳の 2.5%
0%27.7%その他 22.2%

分野

  • Medicine62.9%
  • Neuroscience22.2%
  • Biochemistry, Genetics and Molecular Biology5.5%
  • Psychology4.5%
  • Computer Science2.3%
  • Health Professions0.4%
  • その他2.2%

トピック

  • Parkinson's Disease Mechanisms and Treatments10.7%
  • Neurological disorders and treatments7%
  • Alzheimer's disease research and treatments6.8%
  • Dementia and Cognitive Impairment Research5.6%
  • Neurotransmitter Receptor Influence on Behavior4.2%
  • Functional Brain Connectivity Studies3.4%
  • その他62.3%

共著者

全論文

検索で開く
  1. The Parkinson Progression Marker Initiative (PPMI)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Keith A. Hawkins, Jamie L. Eberling, Deborah W. Brooks, David Russell, Laura Leary, Stewart A. Factor, Barbara Sommerfeld, Penelope Hogarth, Emily Pighetti, Karen Williams, David G. Standaert, Stephanie Guthrie, Robert A. Hauser, Holly Delgado, Joseph Jankovic, Christine Hunter, Matthew Stern, Baochan Tran, Jim Leverenz, Marne Baca, Sam Frank, Cathi-Ann Thomas, Irene Hegeman Richard, Cheryl Deeley, Linda Rees, Fabienne Sprenger, Elisabeth Lang, Holly A. Shill, Sanja Obradov, Hubert Fernandez, Adrienna Winters, Daniela Berg, Katharina Gauss, Douglas Galasko, Deborah Fontaine, Zoltán Mari, Melissa Gerstenhaber, David J. Brooks, Sophie Malloy, Paolo Barone, Katia Longo, Tom Comery, Bernard Ravina, Igor D. Grachev, Kim P. Gallagher, Michelle Collins, Katherine L. Widnell, Suzanne Ostrowizki, Paulo Fontoura, Tony W. Ho, Johan Luthman, Marcel van der Brug, Alastair D. Reith, Peggy Taylor - Progress in Neurobiology 2011 被引用: 1,915

  2. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2023 被引用: 693

  3. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel Weintraub, Yuge Xiao, Andrew Siderowf, Billy Dunn, Kenneth Marek - The Lancet Neurology 2024 被引用: 563

  4. CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

    著者: , , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2018 被引用: 829

  5. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Clinical and Translational Neurology 2018 被引用: 686

  6. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2015 被引用: 609

  7. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kai Bötzel, Joseph Claßen, Peter Bartenstein, Victor L. Villemagne, Johannes Levin, Günter U. Höglinger, Alexander Drzezga, John Seibyl, Osama Sabri - JAMA Neurology 2020 被引用: 253

  8. Tau deposition patterns are associated with functional connectivity in primary tauopathies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jost J. Rumpf, Matthias L. Schroeter, Joseph Claßen, Victor L. Villemagne, John Seibyl, Andrew Stephens, Edward B. Lee, David G. Coughlin, Armin Giese, Murray Grossman, Corey T. McMillan, Ellen Gelpí, Laura Molina‐Porcel, Yaroslau Compta, John C. van Swieten, Laura Donker Laat, Claire Troakes, Safa Al‐Sarraj, John Robinson, Sharon X. Xie, David J. Irwin, Sigrun Roeber, Jochen Herms, Mikael Simons, Peter Bartenstein, Virginia M. Lee, John Q. Trojanowski, Johannes Levin, Günter U. Höglinger, Michael Ewers - Nature Communications 2022 被引用: 108

  9. Targeting Prodromal Alzheimer Disease With Avagacestat

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Neurology 2015 被引用: 233

  10. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Movement Disorders 2020 被引用: 201

  11. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2020 被引用: 257

  12. SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0

    著者: , , , , , , , , , , , , - Journal of Nuclear Medicine 2016 被引用: 258

  13. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Alzheimer s Disease 2017 被引用: 217

  14. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Movement Disorders 2018 被引用: 205

  15. Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study

    著者: , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2019 被引用: 200

  16. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study

    著者: , , , , , , , , , , - The Lancet Neurology 2011 被引用: 586

  17. Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

    著者: , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2012 被引用: 399

  18. Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression

    著者: , , , , , , , , , , - Movement Disorders 2021 被引用: 66

  19. MRI-based measurement of hippocampal volume in patients with combat- related posttraumatic stress disorder

    著者: , , , , , , , , , - American Journal of Psychiatry 1995 被引用: 1,611

  20. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter–Deficit Prodromal Cohort

    著者: , , , , , , , - JAMA Neurology 2017 被引用: 198

  21. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease

    著者: , , , , , , , , - Brain 2015 被引用: 219

  22. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

    著者: , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1996 被引用: 1,294

  23. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John Seibyl, Susan Mendick, Norbert Schuff, Chelsea Caspell, Liz Uribe, Eric D. Foster, Katherine B. Gloer, Jon Yankey, Arthur W. Toga, Karen Crawford, Paola Casalin, Giulia Malferrari, Brit Mollenhauer, Douglas Galasko, Andrew Singleton, Keith A. Hawkins, David Russell, Stewart A. Factor, Penelope Hogarth, David G. Standaert, Robert A. Hauser, Joseph Jankovic, Matthew Stern, Lana M. Chahine, James B. Leverenz, Samuel Frank, Irene Richard, Klaus Seppi, Holly A. Shill, Hubert Fernandez, Daniela Berg, Isabel Wurster, Douglas Galasko, Zoltan Mari, David J. Brooks, Nicola Pavese, Paolo Barone, Stuart Isaacson, Alberto J. Espay, Dominic B. Rowe, Melanie Brandabur, James W. Tetrud, Grace Liang, Álex Iranzo, Eduardo Tolosa, Laura Leary, C Riordan, Linda Rees, Alicia Portillo, Art Lenahan, Karen Williams, Stephanie Guthrie, Ashlee Brooke Rawlins, Sherry Harlan, Christine Hunter, Baochan Tran, Abigail Darin, Carly Linder, Marne Baca, Heli Venkov, Cathi-Ann Thomas, Raymond James, Cheryl Deeley, Courtney Bishop, Fabienne Sprenger, Diana Willeke, Sanja Obradov, Jennifer Mule, Nancy Monahan, Katharina Gauss ほか 98 名 - Neurology 2017 被引用: 152

  24. Signs and Artifacts in Amyloid PET

    著者: , , , , - Radiographics 2018 被引用: 89